Literature DB >> 34173298

Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34173298      PMCID： PMC8262312          DOI： 10.1002/onco.13873

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  2 in total

1.  Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

Authors:  Dejan Juric; Filip Janku; Jordi Rodón; Howard A Burris; Ingrid A Mayer; Martin Schuler; Ruth Seggewiss-Bernhardt; Marta Gil-Martin; Mark R Middleton; José Baselga; Douglas Bootle; David Demanse; Lars Blumenstein; Karl Schumacher; Alan Huang; Cornelia Quadt; Hope S Rugo
Journal:  JAMA Oncol       Date:  2019-02-14       Impact factor: 31.777

2.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.